Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12516306 | 0.90 | NPC1 (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12515769 | 0.88 | HDAC1 (0.51) | KMT2AKDM4EALDH1A1HPGDRXFP1 | |
| SCHEMBL12516706 | 0.88 | MET (0.41) | KMT2AKDM4EALDH1A1HPGDTSHR | |
| SCHEMBL12516286 | 0.88 | HPGD (0.50) | KMT2AHPGDCYP1A2CYP2C19GAA | |
| SCHEMBL27908402 | 0.88 | MET (0.43) | HDAC1HDAC6 | |
| SCHEMBL29829522 | 0.88 | MET (0.43) | HDAC1HDAC6 | |
| SCHEMBL1503237 | 0.87 | KMT2A (0.45) | KMT2AKDM4EALDH1A1HPGDTSHR | |
| SCHEMBL12515589 | 0.85 | HDAC1 (0.53) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL29829563 | 0.85 | HDAC1 (0.52) | EGLN1HDAC1HDAC6 | |
| SCHEMBL1503191 | 0.85 | HDAC1 (0.52) | EGLN1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8664248-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | TAIMED BIOLOGICS, INC. (TW) | 2014-03-04 | — | — | US | disclosed |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA, INC. (CA) | 2012-12-27 | — | — | US | disclosed |
| EP-2526091-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TaiMed Biologics, Inc. (TW) | 2012-11-28 | — | — | EP | disclosed |
| US-8283366-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | AMBRILIA BIOPHARMA, INC. (CA) | 2012-10-09 | — | — | US | disclosed |
| WO-2011088549-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA INC. (CA) | 2011-07-28 | — | — | WO | disclosed |
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TAIMED BIOLOGICS, INC. (TW) | 2011-07-28 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| EP-2300433-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | Ambrilia Biopharma Inc. (CA) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009146555-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | KMT2A 2997/4885KDM4E 875/4885ALDH1A1 526/4885 |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | KMT2A 1953/4885KDM4E 1182/4885ALDH1A1 334/4885 |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | KMT2A 2997/4885KDM4E 875/4885ALDH1A1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.